Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Loxapine Succinate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,104Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 27833-64-3, Loxapine succinate salt, Loxapac, Cloxazepin, Daxolin, Loxapine (succinate)
    Molecular Formula
    C22H24ClN3O5
    Molecular Weight
    445.9  g/mol
    InChI Key
    YQZBAXDVDZTKEQ-UHFFFAOYSA-N
    FDA UNII
    X59SG0MRYU
    An antipsychotic agent used in schizophrenia.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    butanedioic acid;8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
    2.1.2 InChI
    InChI=1S/C18H18ClN3O.C4H6O4/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18;5-3(6)1-2-4(7)8/h2-7,12H,8-11H2,1H3;1-2H2,(H,5,6)(H,7,8)
    2.1.3 InChI Key
    YQZBAXDVDZTKEQ-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    X59SG0MRYU
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 2-chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine

    2. Cl 71,563

    3. Cl-71,563

    4. Cl71,563

    5. Cloxazepine

    6. Hydrochloride, Loxapine

    7. Loxapine

    8. Loxapine Hydrochloride

    9. Loxapine Monohydrochloride

    10. Loxapinsuccinate

    11. Loxipine Maleate

    12. Loxipine Succinate

    13. Loxitane

    14. Maleate, Loxipine

    15. Oxilapine

    16. Succinate, Loxapine

    2.3.2 Depositor-Supplied Synonyms

    1. 27833-64-3

    2. Loxapine Succinate Salt

    3. Loxapac

    4. Cloxazepin

    5. Daxolin

    6. Loxapine (succinate)

    7. Loxapine, Succinate

    8. Cl 71563

    9. Loxapine,succinate

    10. X59sg0mryu

    11. Nsc-759578

    12. Cl-71563

    13. Cpd000058470

    14. Mls000069383

    15. Butanedioic Acid, Compd. With 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine (1:1)

    16. Ncgc00016160-02

    17. Lederle

    18. Smr000058470

    19. Cas-27833-64-3

    20. Dsstox_cid_25227

    21. Dsstox_rid_80764

    22. Dsstox_gsid_45227

    23. 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine Succinate (1:1)

    24. Chebi:6549

    25. Loxapine Succinate [usan]

    26. Butanedioic Acid;8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine

    27. Butanedioic Acid, Compd. With 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine (1:1)

    28. Ccris 1917

    29. Az-004

    30. Sr-01000002971

    31. Einecs 248-682-0

    32. Unii-x59sg0mryu

    33. Loxapine Succinate [usan:usp]

    34. Staccato-loxapine

    35. Loxitane (tn)

    36. Prestwick_304

    37. Mfcd00069298

    38. Lopac-l-106

    39. Opera_id_1518

    40. Loxapine Succinate (usp)

    41. 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine Succinate

    42. Schembl41643

    43. Maprotilinehydrochloride

    44. Mls000758291

    45. Mls001146961

    46. Mls001401432

    47. Mls002222201

    48. Spectrum2300242

    49. Loxapine Succinate Salt, Solid

    50. Regid_for_cid_71399

    51. Loxapine Succinate [mi]

    52. Chembl1201155

    53. Dtxsid3045227

    54. Hms1568k06

    55. Hms1922l14

    56. Hms2051e05

    57. Hms2093n20

    58. Hms2095k06

    59. Hms2232n05

    60. Hms3262o21

    61. Hms3374f02

    62. Hms3393e05

    63. Hms3652o10

    64. Hms3712k06

    65. Hms3885h03

    66. Loxapine Succinate [vandf]

    67. Pharmakon1600-02300242

    68. Loxapine Succinate [mart.]

    69. Loxapine Succinate [usp-rs]

    70. Loxapine Succinate [who-dd]

    71. Tox21_110311

    72. Tox21_500720

    73. Az-104

    74. Ccg-39497

    75. Hy-17390a

    76. Nsc759578

    77. S4086

    78. Akos015994711

    79. Tox21_110311_1

    80. Cs-4285

    81. Ks-1083

    82. Lp00720

    83. Nc00011

    84. Nsc 759578

    85. Loxapine Succinate [orange Book]

    86. Ncgc00016160-01

    87. Ncgc00016160-03

    88. Ncgc00016160-04

    89. Ncgc00016160-05

    90. Ncgc00021145-11

    91. Ncgc00094068-01

    92. Ncgc00094068-02

    93. Ncgc00094068-03

    94. Ncgc00261405-01

    95. Loxapine Succinate [usp Monograph]

    96. Succinic Acid, Compd. With 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine (1:1)

    97. Succinic Acid, Compound With 2-chloro-11-(4-methylpiperazin-1-yl)dibenz(b,f)(1,4)oxazepine (1:1)

    98. Eu-0100720

    99. Ft-0653022

    100. Sw196603-4

    101. Vu0239541-8

    102. D00794

    103. F14786

    104. 833l643

    105. Sr-01000002971-2

    106. Sr-01000002971-6

    107. Sr-01000002971-9

    108. W-107092

    109. Q27107236

    110. 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine Succinate

    111. 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepinesuccinate

    112. Loxapine Succinate, United States Pharmacopeia (usp) Reference Standard

    113. (e)-2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine Succinate

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 445.9 g/mol
    Molecular Formula C22H24ClN3O5
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count4
    Exact Mass445.1404486 g/mol
    Monoisotopic Mass445.1404486 g/mol
    Topological Polar Surface Area103 Ų
    Heavy Atom Count31
    Formal Charge0
    Complexity542
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameLoxapine succinate
    Drug LabelLoxapine, a dibenzoxazepine compound, represents a subclass of tricyclic antipsychotic agents, chemically distinct from the thioxanthenes, butyrophenones, and phenothiazines. Chemically, it is 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxaze...
    Active IngredientLoxapine succinate
    Dosage FormCapsule
    RouteOral
    Strengtheq 5mg base; eq 50mg base; eq 10mg base; eq 25mg base
    Market StatusPrescription
    CompanyLannett Holdings; Watson Labs; Mikah Pharma; Mylan

    2 of 2  
    Drug NameLoxapine succinate
    Drug LabelLoxapine, a dibenzoxazepine compound, represents a subclass of tricyclic antipsychotic agents, chemically distinct from the thioxanthenes, butyrophenones, and phenothiazines. Chemically, it is 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxaze...
    Active IngredientLoxapine succinate
    Dosage FormCapsule
    RouteOral
    Strengtheq 5mg base; eq 50mg base; eq 10mg base; eq 25mg base
    Market StatusPrescription
    CompanyLannett Holdings; Watson Labs; Mikah Pharma; Mylan

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Antipsychotic Agents

    Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)

    Dopamine Antagonists

    Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)